Search

Your search keyword '"Shao, Yu-Yun"' showing total 396 results
Start Over Author "Shao, Yu-Yun"
396 results on '"Shao, Yu-Yun"'

53. An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma

Author

Shen, Ying-Chun, primary, Lee, Pei-Chang, additional, Kuo, Yu-Lun, additional, Wu, Wei-Kai, additional, Chen, Chieh-Chang, additional, Lei, Chengh-Hau, additional, Yeh, Ching-Ping, additional, Hsu, Chiun, additional, Hsu, Chih-Hung, additional, Lin, Zhong-Zhe, additional, Shao, Yu-Yun, additional, Lu, Li-Chun, additional, Liu, Tsung-Hao, additional, Chen, Chien-Hung, additional, Wu, Ming-Shiang, additional, Huang, Yi-Hsiang, additional, and Cheng, Ann-Lii, additional

Published
2021
Full Text
View/download PDF

62. Abstract 1590: High ICOS/FOXP3 Tregs content in the tumor microenvironment is associated with poorer survival in patients with hepatocellular carcinoma

Author

Lu, Li-Chun, primary, Deantonio, Cecilia, additional, Mitchell, Laura, additional, Lee, Yi-Hsuan, additional, Shao, Yu-Yun, additional, Chen, Ron, additional, Cowan, Marianne, additional, Corser, Matthew, additional, Sherry, Lorcan, additional, Cheng, Ann-Lii, additional, Lin, Chia-Chi, additional, Quaratino, Sonia, additional, Sainson, Richard C., additional, and Hsu, Chih-Hung, additional

Published
2020
Full Text
View/download PDF

64. A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy

Author

Lin, Zhong-Zhe, primary, Chen, Bang-Bin, additional, Hung, Yi-Ping, additional, Huang, Po-Hsiang, additional, Shen, Ying-Chun, additional, Shao, Yu-Yun, additional, Hsu, Chih-Hung, additional, Cheng, Ann-Lii, additional, Lee, Rheun-Chuan, additional, Chao, Yee, additional, and Hsu, Chiun, additional

Published
2020
Full Text
View/download PDF

65. Satisfaction with pain management and impact of pain on quality of life in cancer patients

Author

Lin, Johnson, primary, Hsieh, Ruey‐Kuen, additional, Chen, Jen‐Shi, additional, Lee, Kuan‐Der, additional, Rau, Kun‐Ming, additional, Shao, Yu‐Yun, additional, Sung, Yung‐Chuan, additional, Yeh, Su‐Peng, additional, Chang, Cheng‐Shyong, additional, Liu, Ta‐Chih, additional, Wu, Ming‐Fang, additional, Lee, Ming‐Yang, additional, Yu, Ming‐Sun, additional, Yen, Chia‐Jui, additional, Lai, Pang‐Yu, additional, Hwang, Wen‐Li, additional, and Chiou, Tzeon‐Jye, additional

Published
2020
Full Text
View/download PDF

75. Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Author

Lu, Li-Chun, primary, Hsu, Chiun, additional, Shao, Yu-Yun, additional, Chao, Yee, additional, Yen, Chia-Jui, additional, Shih, I-Lun, additional, Hung, Yi-Ping, additional, Chang, Chun-Jung, additional, Shen, Ying-Chun, additional, Guo, Jhe-Cyuan, additional, Liu, Tsung-Hao, additional, Hsu, Chih-Hung, additional, and Cheng, Ann-Lii, additional

Published
2019
Full Text
View/download PDF

76. A nationwide survey of adherence to analgesic drugs among cancer patients in Taiwan: prevalence, determinants, and impact on quality of life

Author

Chou, Wen-Chi, primary, Chen, Jen-Shi, additional, Hung, Chia-Yen, additional, Lu, Chang-Hsien, additional, Shao, Yu-Yun, additional, Chiou, Tzeon-Jye, additional, Sung, Yung-Chuan, additional, Rau, Kun-Ming, additional, Yen, Chia-Jui, additional, Yeh, Su-Peng, additional, Liu, Ta-Chih, additional, Wu, Ming-Fang, additional, Lee, Ming-Yang, additional, Yu, Ming-Sun, additional, Hwang, Wen-Li, additional, Lai, Pang-Yu, additional, Chang, Cheng-Shyong, additional, and Hsieh, Ruey-Kuen, additional

Published
2018
Full Text
View/download PDF

77. Patients with head and neck cancer may need more intensive pain management to maintain daily functioning: a multi-center study

Author

Cho, Shih-Feng, primary, Rau, Kun-Ming, additional, Shao, Yu-Yun, additional, Yen, Chia-Jui, additional, Wu, Ming-Fang, additional, Chen, Jen-Shi, additional, Chang, Cheng-Shyong, additional, Yeh, Su-Peng, additional, Chiou, Tzeon-Jye, additional, Hsieh, Ruey-Kuen, additional, Lee, Ming-Yang, additional, Sung, Yung-Chuan, additional, Lee, Kuan-Der, additional, Lai, Pang-Yu, additional, Yu, Ming-Sun, additional, Hwang, Wen-Li, additional, and Liu, Ta-Chih, additional

Published
2018
Full Text
View/download PDF

79. Abstract 3627: Organ-specific differential responses to immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma

Author

Lu, Li-Chun, primary, Hsu, Chiun, additional, Shao, Yu-Yun, additional, Chao, Yee, additional, Yen, Chia-Jui, additional, Shih, I-Lun, additional, Hung, Yi-Ping, additional, Chang, Chun-Jung, additional, Shen, Ying-Chun, additional, Guo, Jhe-Cyuan, additional, Liu, Tsung-hao, additional, Hsu, Chih-Hung, additional, and Cheng, Ann-Lii, additional

Published
2018
Full Text
View/download PDF

93. Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives

Author

Cheng, Ann-Lii, Hsu,Chih-Hung, Shen,Ying-Chun, Shao,Yu-Yun, and Hsu,Chiun

Subjects
neoplasms, digestive system diseases, Journal of Hepatocellular Carcinoma
Abstract

Chih-Hung Hsu,1,4 Ying-Chun Shen,1,2 Yu-Yun Shao,1,4 Chiun Hsu,1,4 Ann-Lii Cheng,1,3,41Department of Oncology, 2Department of Medical Research, 3Department of Internal Medicine, National Taiwan University Hospital, 4Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, TaiwanAbstract: The approval of sorafenib, a multikinase inhibitor targeting primarily Raf kinase and the vascular endothelial growth factor receptor, in 2007 for treating advanced hepatocellular carcinoma (HCC) has generated considerable enthusiasm in drug development for this difficult-to-treat disease. However, because several randomized Phase III studies testing new multikinase inhibitors failed, sorafenib remains the standard of first-line systemic therapy for patients with advanced HCC. Field practice studies worldwide have suggested that in daily practice, physicians are adopting either a preemptive dose modification or a ramp-up strategy to improve the compliance of their patients. In addition, accumulating data have suggested that patients with Child–Pugh class B liver function can tolerate sorafenib as well as patients with Child–Pugh class A liver function, although the actual benefit of sorafenib in patients with Child–Pugh class B liver function has yet to be confirmed. Whether sorafenib can be used as an adjunctive therapy to improve the outcomes of intermediate-stage HCC patients treated with transcatheter arterial chemoembolization or early-stage HCC patients after curative therapies is being investigated in several ongoing randomized Phase III studies. An increasing number of studies have reported that sorafenib exerts "off-target" effects, including the modulation of signaling pathways other than Raf/MEK/ERK pathway, nonapoptotic cell death mechanisms, and even immune modulation. Finally, although sorafenib in combination with chemotherapy or other targeted therapies has the potential to improve therapeutic efficacy in treating HCC, it also increases toxicity. Additional clinical studies are warranted to determine useful sorafenib-based combinations for the treatment of advanced HCC.Keywords: HCC, multikinase inhibitor, advanced stage, sorafenib

Published
2014

100. Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment

Author

Lu, Li-Chun, Lee, Yi-Hsuan, Chang, Chun-Jung, Shun, Chia-Tung, Fang, Chih-Yeu, Shao, Yu-Yun, Liu, Tsung-Hao, Cheng, Ann-Lii, and Hsu, Chih-Hung

Abstract

Objective:Programmed death-ligand 1 (PD-L1) expression in the tumor microenvironment (TME) has been reported to be related to prognosis in patients with hepatocellular carcinoma (HCC) after hepatectomy. The impact of sorafenib on PD-L1 expression in the TME of advanced HCC is unclear. Patients and Methods:Patients with HCC who received sorafenib for advanced disease at National Taiwan University Hospital, Taipei, Taiwan, and who had paired HCC tissues obtained before and after sorafenib treatment were included in the study group. HCC patients not treated with sorafenib who had paired primary and recurrent or metastatic tissues were identified as the reference group. The membrane PD-L1 staining, detected by immunohistochemistry (IHC) using SP142 antibody, was semiquantitatively scored in tumor cells (TCs) or tumor-infiltrating immune cells (ICs). Additional IHC assays were employed to characterize the PD-L1-expressing ICs. Results:Twenty-three advanced HCC patients with pre- and post-sorafenib paired HCC tissues were included in the study group. The median duration of sorafenib treatment was 4.3 months (range: 1.3–18.7). PD-L1 expression in ICs was significantly higher in post-sorafenib HCC tissues than in pre-sorafenib HCC tissues (pre-sorafenib vs. post-sorafenib IHC 0/1/2/3: 11/5/5/2 vs. 5/5/2/11, p= 0.016). However, PD-L1 expression in TCs was not significantly different between pre- and post-sorafenib tissues (IHC 0/1/2/3: 19/2/0/2 vs. 14/5/0/4, p= 0.094). In the reference group of 44 patients not treated with sorafenib, PD-L1 expression in ICs and TCs was not significantly different between the paired primary andmetastatic HCC tissues. By performing IHC double staining with PD-L1 and CD68, we found the PD-L1-expressing ICs were mainly CD68-positive macrophages. PD-L1 expression levels of pre- and post-sorafenib tissues were not associated with patients’ overall survival or duration of sorafenib treatment. Conclusions:PD-L1 expression in ICs was significantly increased in post-sorafenib HCC tissues. The mechanisms and clinical significance of this observation warrants further investigation.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results